MK-2866 (Ostarine) + GW-0742 (Fitorine) | SARMs & Metabolic Research UK

Lean Tissue & Metabolic Research Set

The BioPlex Lean Tissue & Metabolic Research Set combines MK-2866 (Ostarine) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together two research compounds associated with distinctly different molecular pathways. The set contains one pot of each compound and provides a structured format for comparative laboratory investigation of androgen-receptor signalling alongside PPARδ-associated metabolic signalling.

MK-2866, commonly known as Ostarine and also associated with the developmental name Enobosarm, is a non-steroidal selective androgen receptor modulator. Its research history includes investigation of androgen-receptor activity, tissue-selective signalling, lean-tissue-related measurements and other controlled biological endpoints. This makes Ostarine one of the more extensively characterised compounds within the wider SARM research category.

GW-0742, presented by BioPlex as Fitorine, belongs to a different pharmacological research category. It is associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. PPARδ is a nuclear receptor involved in transcriptional regulation across metabolic pathways including lipid and fatty-acid handling. GW-0742 should therefore not be classified as a SARM simply because it is sometimes grouped commercially alongside selective androgen receptor modulators.

This difference creates the principal scientific value of the pairing. Researchers can investigate a recognised androgen-receptor ligand alongside a PPARδ-associated research compound while maintaining clear separation between their mechanisms.

The Lean Tissue & Metabolic Research Set name reflects these two areas of investigation rather than suggesting a predetermined combined outcome. It allows tissue-related androgen-receptor research and metabolic-signalling research to be considered within one structured comparative framework.

Both compounds remain individually identified 50×15mg research products intended strictly for laboratory, analytical and educational research.

How MK-2866 and GW-0742 Work Together

MK-2866 (Ostarine) and GW-0742 (Fitorine) provide a distinctive research pairing because their primary molecular pathways differ. MK-2866 is associated principally with selective androgen-receptor modulation, whereas GW-0742 is associated with PPARδ. Their scientific relationship therefore comes from the opportunity to investigate separate regulatory pathways within a broader tissue and metabolic research framework.

The androgen receptor targeted by MK-2866 belongs to the nuclear-receptor family and functions as a ligand-responsive regulator of gene transcription. Interaction with Ostarine can influence receptor conformation, co-regulatory interactions and downstream androgen-responsive transcription. Research has examined these processes in relation to tissue-selective signalling and lean-tissue-associated endpoints.

PPARδ is also a nuclear receptor, but it operates through a different signalling system. Research involving PPARδ has examined transcriptional regulation associated with lipid handling, fatty-acid metabolism and cellular energy processes. GW-0742 has been used experimentally as a pharmacological tool for investigating this pathway.

Placing MK-2866 and GW-0742 together therefore allows two different nuclear-receptor systems to be studied within the same broader research theme. Researchers may compare predefined tissue-associated and metabolic markers while maintaining compound-specific controls.

The combination does not establish that the compounds are synergistic. Nor does it demonstrate that modulation of one pathway necessarily enhances the other. Cellular signalling involves interconnected biological networks, and experimental responses can vary according to concentration, exposure, receptor expression, tissue type and methodology.

The research value instead comes from pathway comparison. MK-2866 provides a genuine SARM and androgen-receptor research component, while GW-0742 provides a separate PPARδ-associated metabolic component.

This creates a structured laboratory format for examining distinct mechanisms while avoiding the scientifically incorrect classification of GW-0742 as a selective androgen receptor modulator.

MK-2866 (Ostarine) 50×15mg

MK-2866, commonly known as Ostarine and also associated with the developmental name Enobosarm, is a synthetic non-steroidal selective androgen receptor modulator. It has become one of the more extensively investigated compounds within the SARM research field, with research extending beyond early receptor studies into controlled investigation of biological and tissue-related endpoints.

The principal molecular target of MK-2866 is the androgen receptor. This receptor belongs to the nuclear-receptor family and can regulate transcription of androgen-responsive genes following ligand interaction. The resulting experimental response depends upon receptor expression, cellular environment, co-regulatory proteins, exposure and the particular biological endpoint being examined.

Research involving Ostarine has examined tissue-selective androgen-receptor signalling alongside measurements associated with lean tissue and functional outcomes. Its comparatively developed evidence base makes it useful both as an individual experimental compound and as a reference point when investigating other research molecules.

However, classification as a SARM does not mean that every claim associated with Ostarine has been established scientifically. Findings must be interpreted according to study design, research model, exposure duration and measured endpoints. Results from one experimental environment cannot automatically be transferred to another.

Within the Lean Tissue & Metabolic Research Set, MK-2866 provides the androgen-receptor-focused side of the pairing. Its established SARM classification can be considered alongside the distinctly different PPARδ-associated research profile of GW-0742.

This makes the combination particularly useful for comparative pathway research. Rather than studying two compounds from the same pharmacological class, researchers can examine androgen-receptor signalling and metabolic nuclear-receptor signalling separately while considering how selected experimental markers differ across the two research systems.

GW-0742 (Fitorine) 50×15mg

GW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. Its molecular classification is distinct from selective androgen receptor modulators and its principal research pathway should therefore not be confused with androgen-receptor signalling.

PPARδ belongs to the nuclear-receptor superfamily and functions as a transcriptional regulator. Following interaction with suitable ligands, PPAR-associated signalling can influence expression of genes involved in several areas of cellular and metabolic biology.

Research involving PPARδ has examined lipid handling, fatty-acid metabolism, cellular energy regulation and related transcriptional pathways. GW-0742 has been used experimentally as a pharmacological research tool for investigating receptor-associated responses and changes in predefined molecular markers.

The compound's inclusion alongside Ostarine is particularly useful because the two molecules represent different areas of nuclear-receptor research. Ostarine provides a selective androgen-receptor pathway, whereas GW-0742 provides a PPARδ-associated metabolic pathway.

Researchers can therefore examine each compound independently before comparing selected endpoints within a broader tissue and metabolic research framework. This approach preserves the mechanistic differences between the molecules rather than treating commercially grouped research compounds as though they belong to the same pharmacological class.

Receptor classification also does not guarantee a particular experimental outcome. Concentration, exposure, cellular environment, receptor expression and potential off-target activity all require consideration when interpreting findings involving GW-0742.

Within the BioPlex Lean Tissue & Metabolic Research Set, GW-0742 consequently provides the metabolic-signalling component of the pairing. Together with MK-2866, it supports comparative laboratory investigation of two distinct regulatory pathways while maintaining accurate scientific classification.

Explore Related Research Compounds

Continue exploring related androgen-receptor and metabolic research compounds from the BioPlex capsule range.

View MK-2866 Ostarine 50×15mg Research Capsules ⟶

View GW-0742 Fitorine 50×15mg Research Capsules ⟶

View AC-262 Accadrine 50×15mg Research Capsules ⟶

Explore BioPlex Research Information

Access BioPlex research guidance, compound classification and the complete research product range.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore the BioPlex SARMs & Research Compound Range ⟶

View All BioPlex Research Products ⟶

Explore Related Research Articles

Continue your research with BioPlex articles covering Ostarine MK-2866, androgen-receptor signalling, compound classification and related research pathways.

Read the Ostarine MK-2866 Research Overview ⟶

Read the Complete SARMs UK Research Compound Guide ⟶

Explore All BioPlex SARMs Research Articles ⟶

Disclaimer

For research purposes only. Not for human consumption.